Biotech

All Articles

A more detailed look at Brutal Biotech's Brutal 15

.In this full week's episode of "The Best Pipe," our company are actually diving into Brutal Biotech...

Lilly encounters period 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's party celebrating the commendation of Alzhei...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of considerable management hirings, shooting...

Lykos are going to talk to FDA to rethink its own selection observing being rejected of MDMA treatment for post-traumatic stress disorder

.Following an unsatisfactory showing for Lykos Rehabs' MDMA candidate for trauma at a current FDA co...

AN 2 halves census, ceases phase 3 test after records disappoint

.AN2 Therapies is actually rethinking its organization in action to lackluster midphase data, promis...

Merck spends $700M for bispecific, snooping autoimmune position as well as odds to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying $700 million ahead of time to test Amgen in a blood cancer cells ...

Gilead pays J&ampJ $320M to exit licensing deal for seladelpar

.Along With Gilead Sciences about to an FDA choice for its own liver illness medication seladelpar, ...

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks may observe the providers putting together camping tents at basecamp behind Eli Lil...

Entero giving up workers, vacating workplace and stopping briefly R&ampD

.Cushion Liquidators has switched Entero Therapeutics white colored as a sheet. The lender purchased...

Exelixis loses ADC after deciding it's no suit for Tivdak

.Exelixis is actually giving up on its own tissue variable (TF)- targeting antibody-drug conjugate a...